Nanomix Inc., a leading nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced that the Japanese Patent Office has allowed a design patent application relating to the Nanomix single-use cartridge. The single use, multiplex microfluidic test cartridge is a key aspect of the Nanomix POC system which also includes a mobile handheld reader. The system is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample. The patent strengthens Nanomix’s already robust patent portfolio covering both technology and product implementations.

The global market for POC testing is expected to grow from over $6B today to $8.9B by 2016. This growth will be fueled by the drive for lower cost diagnostic systems that provide reliable results faster to physicians and patients. Japan represents about 10% of the $1B global POC market for cardiac testing.